BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
BUSINESS STRATEGY: Continue to build on our technological lead in the area of biotechnology and
nanotechnology and in the long term to become market leader in the areas
of our core competencies. Alone or with competent partners and strategic
alliances, we will occupy market niches and develop new markets. The
products of november AG are needed worldwide.
RESEARCH & DEVELOPMENT: Labeling/tracing
Product authentication
DNA diagnostics
Product security and brand protection
PRODUCTS ON MARKET: Molecular fingerprint (DNA codes) and nano-optical seal (cluster codes)=
novel marking systems for brand protection & product security
PRODUCTS IN DEVELOPMENT: Name Status
Biological eartag: bioactive labeling of
livestock
in development
System for fully automated, rapid and
laboratory-independent nucleic acid testing
in development
Immune therapies for a variety of medical
indications
in clinicals
Noven Pharmaceuticals Inc.
11960 S.W. 144th Street
Miami FL 33186, US
Phone: (305) 253-5099; Fax: (305) 251-1887
Web: www.noven.com
KEY PERSONNEL: Robert C. Strauss; Chairman, President and CEO
Diane M. Barrett; VP and CFO
Jeffrey Eisenberg; Sr. VP, Strategic Alliances
Juan Mantelle; VP and CTO
W. Neil Jones; VP, Sales and Marketing
EMPLOYEES: 500 employees
HISTORY: Incorporated in 1987
FACILITIES: 15-acre facility in Miami-Dade County consisting of multiple buildings
totaling 150,000 sq. ft.
STOCK-FINANCIAL HISTORY: NASDAQ--NOVN; Trading halted--12/05
IPO--2.25M shares of common stock (1988)
Secondary public offering--2.749M shares of common stock at $7/share
(4/92)
Revenue $52.532M (YE 05) compared to $45.891M (YE 04)
Net income $9.972M (YE 05) compared to $11.224M (YE 04)
Earnings per share $0.42/share (YE 05) compared to $0.48/share (YE 04)
Average shares outstanding 23.665M (YE 05) compared to 23.332M (YE
04)
Total assets $185.910M (YE 05) compared to $201.975M (YE 04)
PRIVATE PLACEMENTS: Raised $800K in private sale of 589K shares of common stock (7/91)
SUBSIDIARIES/DIVISIONS: Novogyne Pharmaceuticals--a women’s health products company jointly
owned by Noven and Novartis Pharmaceuticals Corp.
BUSINESS STRATEGY: Maintain a position as a leader in the development of advanced drug
delivery technologies, while concurrently striving to become the world’s
premier transdermal drug delivery company, through development of a
series of groundbreaking products
Copyright ©2006 AHC Media ® 284